Skip to main content

ATAI

Stock

ATAI

Stock
Health Care
Biotechnology

Performance overview

ATAI Price
Price Chart

Forward-looking statistics

Beta
1.17
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

Company info

SectorHealth Care
IndustryBiotechnology
Employees99
Market cap$232.7M

Fundamentals

Enterprise value$369.7M
Revenue$1.9M
Revenue per employee—
Profit margin0.00%
Debt to equity19.02

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)-$0.91
Dividend per share—
Revenue per share$0.01
Avg trading volume (30 day)$12M
Avg trading volume (10 day)$22M
Put-call ratio—

Macro factor sensitivity

Growth+1.6
Credit-7.2
Liquidity+3.6
Inflation-2.3
Commodities+0.8
Interest Rates-1.4

Valuation

Dividend yield0.00%
PEG Ratio-4.07
Price to sales315.43
P/E Ratio-4.07
Enterprise Value to Revenue198.46
Price to book3.64

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day—
Ex. dividend day—

News

Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?

Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

Zacks Investment Research (July 11, 2025)
Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

Atai Life Sciences ATAI and Beckley Psytech Limited jointly announced topline results from the eight-week, quadruple-masked, dose-finding core stage of the Phase 2b trial of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients with treatment-resistant depression (TRD).

Benzinga (July 1, 2025)
The stock of psychedelics giant Atai is tumbling after a treatment failed to help patients in a trial

Atai Life Sciences' ketamine-based therapy failed to help patients with depression in a mid-stage trial.

Business Insider (January 6, 2023)
Atai shares pop after earnings: Company's CEO talks about mental health and psychedelics

Atai Life Sciences, a biopharmaceutical and psychedelic company reported its first earnings since going public in June. Florian Brand, Atai's CEO and co-founder joins Closing Bell to discuss the future of his company and bringing its product to market.

CNBC Television (August 16, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free